関連する実験動画

Updated: Sep 10, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

限られた皮膚性全身性硬化症における血管拡張剤療法後の肺性静脈閉塞性疾患の解明

Nanditha Sidda¹, Rama Bhat², Praveen Tirlangi³

¹General Medicine, Kasturba Medical College Manipal, Manipal, Karnataka, India.

BMJ case reports

|August 27, 2025

まとめ

肺静脈閉塞性疾患 (PVOD) は,肺動脈高血圧 (PAH) と誤解される肺動脈高血圧の珍しい原因です. PAHの治療はPVOD患者に害を与える可能性があるため,PVODを区別することは非常に重要です.

科学分野:

心血管医学
肺医学
リウマトロジ

背景:

肺静脈閉塞症 (PVOD) は,肺高血圧の希少で重症な形態である.
PVODは,線維症と内臓増殖による肺静脈閉塞によって特徴付けられます.
PVODを肺動脈高血圧 (PAH) として誤診すると,治療の結果が悪くなる可能性があります.

研究の目的:

系統性硬化症 (SSc) とPVODとの間の珍しい関連性を強調する.
SSc患者におけるPVODとPAHの区別の重要性を強調する.
SScに関連したPVODに合わせた診断と治療方法の必要性を強調する.

主な方法:

進行性呼吸不全を呈する皮膚性SScの患者の症例報告
PVODとPAHを区別する際の診断上の課題と治療への影響について
臨床評価と病歴分析

主要な成果:

当初PAHと診断された患者は,肺血管拡張剤を投与した後に症状が悪化した.
この有害な結果は,PVODの誤診の可能性を示唆しています.
このケースは,SScとPVODの間の珍しいが重要なリンクを強調しています.

結論:

PVODは,肺高血圧を呈するSSc患者の場合,特に血管拡張剤で悪化した場合に考慮する必要があります.
PVODとPAHを正確に区別することは,適切な管理に不可欠です.
肺高血圧のSSc患者にとって,慎重に診断し,治療策を策定することが重要です.

キーワード:

結合組織疾患肺高血圧

さらに関連する動画

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

関連する概念動画

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...

Peripheral Artery Disease IV: Nursing Management

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...